{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T22:15:16Z","timestamp":1794694516302,"version":"4.9.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Finalizzata 2016, grant GR-2016-02363223"],"award-info":[{"award-number":["Ricerca Finalizzata 2016, grant GR-2016-02363223"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite advances in therapeutic strategies a significant proportion of acute coronary syndrome (ACS) patients experience early coronary artery disease (CAD) progression, particularly those with diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate CAD progression in diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1Ra) over 1 year after an ACS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients presenting with non\u2013ST-elevation ACS between 2019 and 2022 were enrolled in a prospective registry and underwent serial coronary computed tomography angiography (CCTA) at baseline (after revascularization, during the index hospitalization) and at 1-year follow-up. The primary endpoint was the absolute change (1 year \u2013 baseline) in non-culprit lesion plaque burden (\u0394PB) on CCTA, with the absolute change in patient percent atheroma volume (\u0394PAV) as a key secondary endpoint. A comprehensive lipidomic, metabolomic, and proteomic plasma assessment was also performed in all GLP-1Ra\u2013treated patients and four randomly selected controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 28 diabetic patients, 7 (25%) with 22 coronary plaques were treated with GLP-1Ra, and 21 (75%) with 65 plaques received other antidiabetic agents. In the 1-year observation frame, both \u0394PB (-5.8\u2009\u00b1\u200912.8% vs. -1.1\u2009\u00b1\u200913.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041) and \u0394PAV (-6.1% [-7.3, -1.8] vs. -0.7% [-2.4, 9.8],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.039) were significantly lower in GLP-1Ra-treated patients. Total atheroma volume also showed a numerically greater reduction in the GLP-1Ra cohort (0.7\u00a0mm\u00b3 [-2.5-8.7] vs. 25.0\u00a0mm\u00b3 [4.8\u201339.7]), primarily due to a decrease in plaque fibrofatty volume percentage (-2.9\u2009\u00b1\u200910.1% vs. 1.0\u2009\u00b1\u20096.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.042). Lipidomic, metabolomic, and proteomic analyses identified reductions in monoacylglycerols and triacylglycerols, increases in diacylglycerols and phosphatidylethanolamine, a shift from carbohydrate metabolism toward lipid metabolism and hormone regulation, and differential expression of proteins involved in complement activation, endothelial function, and cytoskeletal organization in GLP-1Ra\u2013treated patients compared with controls.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In diabetic patients with ACS, GLP-1Ra therapy was associated with a significant regression in coronary plaque burden at 1 year, supported by favorable lipidomic, metabolomic, and proteomic changes. These findings suggest a potential role for GLP-1Ra in modifying atherosclerosis progression beyond glycemic control.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00592-025-02606-z","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:51:59Z","timestamp":1762257119000},"page":"179-191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["GLP-1 receptor agonists and coronary plaques regression in diabetic patients after acute coronary syndromes"],"prefix":"10.1007","volume":"63","author":[{"given":"Mauro","family":"Gitto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Francone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Mincione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Scial\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo A.","family":"Pivato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza","family":"Lisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Regazzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Maria","family":"Fiorina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Petrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Bucciarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Loretelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Condorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fiorina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-6967","authenticated-orcid":false,"given":"Giulio","family":"Stefanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"issue":"8","key":"2606_CR1","doi-asserted-by":"publisher","first-page":"E93","DOI":"10.1161\/CIR.0000000000001123","volume":"147","author":"CW Tsao","year":"2023","unstructured":"Tsao CW, Aday AW, Almarzooq ZI et al (2023) Heart disease and stroke Statistics-2023 update: A report from the American heart association. Circulation 147(8):E93\u2013E621. https:\/\/doi.org\/10.1161\/CIR.0000000000001123","journal-title":"Circulation"},{"issue":"10","key":"2606_CR2","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/J.JACC.2019.12.067","volume":"75","author":"BM Scirica","year":"2020","unstructured":"Scirica BM, Bergmark BA, Morrow DA et al (2020) Nonculprit lesion myocardial infarction following percutaneous coronary intervention in patients with acute coronary syndrome. J Am Coll Cardiol 75(10):1095\u20131106. https:\/\/doi.org\/10.1016\/J.JACC.2019.12.067","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2606_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/J.AMJCARD.2013.08.039","volume":"113","author":"WJ Kikkert","year":"2014","unstructured":"Kikkert WJ, Hoebers LP, Damman P et al (2014) Recurrent myocardial infarction after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am J Cardiol 113(2):229\u2013235. https:\/\/doi.org\/10.1016\/J.AMJCARD.2013.08.039","journal-title":"Am J Cardiol"},{"key":"2606_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/J.AHJ.2019.02.013","volume":"212","author":"MB Yudi","year":"2019","unstructured":"Yudi MB, Clark DJ, Farouque O et al (2019) Trends and predictors of recurrent acute coronary syndrome hospitalizations and unplanned revascularization after index acute myocardial infarction treated with percutaneous coronary intervention. Am Heart J 212:134\u2013143. https:\/\/doi.org\/10.1016\/J.AHJ.2019.02.013","journal-title":"Am Heart J"},{"issue":"11","key":"2606_CR5","doi-asserted-by":"publisher","first-page":"E875","DOI":"10.4244\/EIJ-D-20-00487","volume":"16","author":"GG Stefanini","year":"2020","unstructured":"Stefanini GG, Alfonso F, Barbato E et al (2020) Management of myocardial revascularisation failure: an expert consensus document of the EAPCI. EuroIntervention 16(11):E875\u2013E890. https:\/\/doi.org\/10.4244\/EIJ-D-20-00487","journal-title":"EuroIntervention"},{"key":"2606_CR6","doi-asserted-by":"publisher","unstructured":"Ritsinger V, Saleh N, Lagerqvist B, Norhammar A (2015) High event rate after a first percutaneous coronary intervention in patients with diabetes mellitus: results from the Swedish coronary angiography and angioplasty registry. Circ Cardiovasc Interv 8(6). https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.114.002328","DOI":"10.1161\/CIRCINTERVENTIONS.114.002328"},{"key":"2606_CR7","doi-asserted-by":"publisher","unstructured":"Babes EE, Bustea C, Behl T et al (2022) Acute coronary syndromes in diabetic patients, outcome, revascularization, and antithrombotic therapy. Biomed Pharmacother 148. https:\/\/doi.org\/10.1016\/J.BIOPHA.2022.112772","DOI":"10.1016\/J.BIOPHA.2022.112772"},{"issue":"2","key":"2606_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2174\/1871525719666210809121016","volume":"20","author":"M Gitto","year":"2022","unstructured":"Gitto M, Vrachatis DA, Condorelli G et al (2022) Potential therapeutic benefits of Sodium-Glucose cotransporter 2 inhibitors in the context of ischemic heart failure: A State-of-the-Art review. Cardiovasc Hematol Agents Med Chem 20(2):90\u2013102. https:\/\/doi.org\/10.2174\/1871525719666210809121016","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"issue":"34","key":"2606_CR9","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM et al (2021) 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42(34):3227\u20133337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484","journal-title":"Eur Heart J"},{"issue":"10","key":"2606_CR10","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS et al (2019) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7(10):776\u2013785. https:\/\/doi.org\/10.1016\/S2213-8587(19)30249-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2606_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/J.CMET.2016.06.009","volume":"24","author":"DJ Drucker","year":"2016","unstructured":"Drucker DJ (2016) The cardiovascular biology of Glucagon-like Peptide-1. Cell Metab 24(1):15\u201330. https:\/\/doi.org\/10.1016\/J.CMET.2016.06.009","journal-title":"Cell Metab"},{"key":"2606_CR12","doi-asserted-by":"publisher","unstructured":"Sanada J, Obata A, Obata Y et al (2021) Dulaglutide exerts beneficial anti atherosclerotic effects in ApoE knockout mice with diabetes: the earlier, the better. Sci Rep 11(1). https:\/\/doi.org\/10.1038\/S41598-020-80894-X","DOI":"10.1038\/S41598-020-80894-X"},{"issue":"38","key":"2606_CR13","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/EURHEARTJ\/EHAD191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ et al (2023) 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J 44(38):3720\u20133826. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAD191","journal-title":"Eur Heart J"},{"issue":"3","key":"2606_CR14","doi-asserted-by":"publisher","first-page":"100607","DOI":"10.1016\/J.JSCAI.2023.100607","volume":"2","author":"A Thomas","year":"2023","unstructured":"Thomas A, Gitto M, Shah S et al (2023) Antiplatelet strategies following PCI: A review of trials informing current and future therapies. J Soc Cardiovasc Angiography Interventions 2(3):100607. https:\/\/doi.org\/10.1016\/J.JSCAI.2023.100607","journal-title":"J Soc Cardiovasc Angiography Interventions"},{"issue":"24","key":"2606_CR15","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289\/FORMAT\/EPUB","volume":"137","author":"HM Garcia-Garcia","year":"2018","unstructured":"Garcia-Garcia HM, McFadden EP, Farb A et al (2018) Standardized end point definitions for coronary intervention trials: the academic research consortium-2 consensus document. Circulation 137(24):2635\u20132650. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.029289\/FORMAT\/EPUB","journal-title":"Circulation"},{"issue":"8","key":"2606_CR16","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/S00125-002-0878-6","volume":"45","author":"T Vilsb\u00f8ll","year":"2002","unstructured":"Vilsb\u00f8ll T, Krarup T, Madsbad S, Holst J (2002) Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45(8):1111\u20131119. https:\/\/doi.org\/10.1007\/S00125-002-0878-6","journal-title":"Diabetologia"},{"issue":"2","key":"2606_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1210\/10.1210\/ER.2006-0038","volume":"28","author":"BL Wajchenberg","year":"2007","unstructured":"Wajchenberg BL (2007) beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 28(2):187\u2013218. https:\/\/doi.org\/10.1210\/10.1210\/ER.2006-0038","journal-title":"Endocr Rev"},{"key":"2606_CR18","doi-asserted-by":"publisher","unstructured":"Fei Y, Tsoi MF, Cheung BMY (2019) Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovasc Diabetol 18(1). https:\/\/doi.org\/10.1186\/S12933-019-0916-Z","DOI":"10.1186\/S12933-019-0916-Z"},{"issue":"4","key":"2606_CR19","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2337\/DC21-1113","volume":"45","author":"AK Wright","year":"2022","unstructured":"Wright AK, Carr MJ, Kontopantelis E et al (2022) Primary prevention of cardiovascular and heart failure events with SGLT2 Inhibitors, GLP-1 receptor Agonists, and their combination in type 2 diabetes. Diabetes Care 45(4):909\u2013918. https:\/\/doi.org\/10.2337\/DC21-1113","journal-title":"Diabetes Care"},{"issue":"7","key":"2606_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2174\/1381612829666230217143324","volume":"29","author":"M Gitto","year":"2023","unstructured":"Gitto M, Villaschi A, Federici M, Condorelli G, Stefanini GG (2023) The emerging role of Sodium-glucose cotransporter 2 inhibitors in heart failure. Curr Pharm Des 29(7):481\u2013493. https:\/\/doi.org\/10.2174\/1381612829666230217143324","journal-title":"Curr Pharm Des"},{"issue":"9","key":"2606_CR21","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1161\/CIR.0000000000001040","volume":"145","author":"JJ Joseph","year":"2022","unstructured":"Joseph JJ, Deedwania P, Acharya T et al (2022) Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: A scientific statement from the American heart association. Circulation 145(9):722\u2013759. https:\/\/doi.org\/10.1161\/CIR.0000000000001040","journal-title":"Circulation"},{"issue":"5","key":"2606_CR22","doi-asserted-by":"publisher","first-page":"H1159","DOI":"10.1152\/AJPHEART.00574.2023","volume":"326","author":"B Park","year":"2024","unstructured":"Park B, Bakbak E, Teoh H et al (2024) GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage. Am J Physiol Heart Circ Physiol 326(5):H1159\u2013H1176. https:\/\/doi.org\/10.1152\/AJPHEART.00574.2023","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"7","key":"2606_CR23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/S41569-023-00849-3","volume":"20","author":"JR Ussher","year":"2023","unstructured":"Ussher JR, Drucker DJ (2023) Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol 20(7):463\u2013474. https:\/\/doi.org\/10.1038\/S41569-023-00849-3","journal-title":"Nat Rev Cardiol"},{"key":"2606_CR24","doi-asserted-by":"publisher","unstructured":"Wu Q, Li D, Huang C et al (2022) Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists. Biomed Pharmacother 153. https:\/\/doi.org\/10.1016\/J.BIOPHA.2022.113517","DOI":"10.1016\/J.BIOPHA.2022.113517"},{"issue":"6","key":"2606_CR25","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/J.JACBTS.2018.09.004","volume":"3","author":"G Rakipovski","year":"2018","unstructured":"Rakipovski G, Rolin B, N\u00f8hr J et al (2018) The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE-\/- and LDLr-\/- mice by a mechanism that includes inflammatory pathways. JACC Basic Transl Sci 3(6):844\u2013857. https:\/\/doi.org\/10.1016\/J.JACBTS.2018.09.004","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"2606_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/S13300-020-00962-3","volume":"12","author":"D Nikolic","year":"2021","unstructured":"Nikolic D, Giglio RV, Rizvi AA et al (2021) Liraglutide reduces carotid Intima-Media thickness by reducing small dense Low-Density lipoproteins in a Real-World setting of patients with type 2 diabetes: A novel Anti-Atherogenic effect. Diabetes Ther 12(1):261\u2013274. https:\/\/doi.org\/10.1007\/S13300-020-00962-3","journal-title":"Diabetes Ther"},{"issue":"22","key":"2606_CR27","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1016\/J.JACC.2018.02.079","volume":"71","author":"HJ Chang","year":"2018","unstructured":"Chang HJ, Lin FY, Lee SE et al (2018) Coronary atherosclerotic precursors of acute coronary syndromes. J Am Coll Cardiol 71(22):2511\u20132522. https:\/\/doi.org\/10.1016\/J.JACC.2018.02.079","journal-title":"J Am Coll Cardiol"},{"key":"2606_CR28","doi-asserted-by":"publisher","unstructured":"Homorodean C, Leucuta DC, Ober M et al (2022) Intravascular ultrasound insights into the unstable features of the coronary atherosclerotic plaques: A systematic review and meta-analysis. Eur J Clin Invest 52(1). https:\/\/doi.org\/10.1111\/ECI.13671","DOI":"10.1111\/ECI.13671"},{"issue":"3","key":"2606_CR29","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1056\/NEJMOA1002358","volume":"364","author":"GW Stone","year":"2011","unstructured":"Stone GW, Maehara A, Lansky AJ et al (2011) A prospective natural-history study of coronary atherosclerosis. N Engl J Med 364(3):226\u2013235. https:\/\/doi.org\/10.1056\/NEJMOA1002358","journal-title":"N Engl J Med"},{"issue":"1","key":"2606_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/J.AHJ.2013.10.011","volume":"167","author":"R Vergallo","year":"2014","unstructured":"Vergallo R, Ren X, Yonetsu T et al (2014) Pancoronary plaque vulnerability in patients with acute coronary syndrome and ruptured culprit plaque: a 3-vessel optical coherence tomography study. Am Heart J 167(1):59\u201367. https:\/\/doi.org\/10.1016\/J.AHJ.2013.10.011","journal-title":"Am Heart J"},{"key":"2606_CR31","unstructured":"Budoff MJ (2022) Semaglutide treatment effect on coronary atherosclerosis progression. Diabetes: STOP randomized control trial semaglutide treatment effect on atherosclerosis progression in diabetes: STOP randomized control trial. Presented at the American Heart Association Scientific Sessions 2022, 5\u20137 November 2022, Chicago, IL"},{"key":"2606_CR32","doi-asserted-by":"publisher","unstructured":"Parlevliet ET, Wang Y, Geerling JJ et al (2012) GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice. PLoS ONE 7(11). https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0049152","DOI":"10.1371\/JOURNAL.PONE.0049152"},{"key":"2606_CR33","doi-asserted-by":"publisher","unstructured":"Della Pepa G, Patr\u00edcio BG, Carli F et al (2024) GLP-1 receptor agonist treatment improves fasting and postprandial lipidomic profiles independently of diabetes and weight loss. Diabetes 73(10). https:\/\/doi.org\/10.2337\/DB23-0972","DOI":"10.2337\/DB23-0972"},{"issue":"5","key":"2606_CR34","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1194\/JLR.M074443","volume":"58","author":"L Manner\u00e5s-Holm","year":"2017","unstructured":"Manner\u00e5s-Holm L, Sch\u00f6nke M, Brozinick JT et al (2017) Diacylglycerol kinase \u03b5 deficiency preserves glucose tolerance and modulates lipid metabolism in obese mice. J Lipid Res 58(5):907\u2013915. https:\/\/doi.org\/10.1194\/JLR.M074443","journal-title":"J Lipid Res"},{"issue":"3","key":"2606_CR35","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/DOM.12593","volume":"18","author":"MM Smits","year":"2016","unstructured":"Smits MM, Tonneijck L, Muskiet MHA, Kramer MHH, Cahen DL, van Raalte DH (2016) Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas. Diabetes Obes Metab 18(3):224\u2013235. https:\/\/doi.org\/10.1111\/DOM.12593","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2606_CR36","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/CPHY.C190025","volume":"10","author":"EM Davis","year":"2020","unstructured":"Davis EM, Sandoval DA (2020) Glucagon-Like Peptide-1: actions and influence on pancreatic hormone function. Compr Physiol 10(2):577\u2013595. https:\/\/doi.org\/10.1002\/CPHY.C190025","journal-title":"Compr Physiol"},{"key":"2606_CR37","doi-asserted-by":"publisher","unstructured":"Bendotti G, Montefusco L, Lunati ME et al (2022) The anti-inflammatory and immunological properties of GLP-1 receptor agonists. Pharmacol Res 182. https:\/\/doi.org\/10.1016\/J.PHRS.2022.106320","DOI":"10.1016\/J.PHRS.2022.106320"},{"key":"2606_CR38","doi-asserted-by":"publisher","unstructured":"Lazzaroni E, Ben Nasr M, Loretelli C et al (2021) Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacol Res 171. https:\/\/doi.org\/10.1016\/J.PHRS.2021.105782","DOI":"10.1016\/J.PHRS.2021.105782"},{"issue":"6","key":"2606_CR39","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/J.CMET.2024.05.001","volume":"36","author":"M Ben Nasr","year":"2024","unstructured":"Ben Nasr M, Usuelli V, Dellepiane S et al (2024) Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule. Cell Metab 36(6):1302\u20131319e12. https:\/\/doi.org\/10.1016\/J.CMET.2024.05.001","journal-title":"Cell Metab"},{"issue":"3","key":"2606_CR40","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/DOM.13955","volume":"22","author":"M Husain","year":"2020","unstructured":"Husain M, Bain SC, Jeppesen OK et al (2020) Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab 22(3):442\u2013451. https:\/\/doi.org\/10.1111\/DOM.13955","journal-title":"Diabetes Obes Metab"},{"issue":"10193","key":"2606_CR41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121\u2013130. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3","journal-title":"Lancet"},{"issue":"23","key":"2606_CR42","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMOA1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373(23):2247\u20132257. https:\/\/doi.org\/10.1056\/NEJMOA1509225","journal-title":"N Engl J Med"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02606-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-025-02606-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02606-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:04:27Z","timestamp":1772557467000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-025-02606-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["2606"],"URL":"https:\/\/doi.org\/10.1007\/s00592-025-02606-z","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"4 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was granted by the local Institutional Review Board, and the study was registered on ClinicalTrials.gov (NCT03890822).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}